IL-22 R alpha 1 詳細
Molecule Name
Interleukin-22 receptor
Drug Development Progress
治験薬の数5
市販薬剤の数0
研究＆開発段階Phase 2 Clinical
ターゲットの別称
バックグランド
Interleukin-22 receptor subunit alpha-1(IL22RA1) is a component of the receptor for IL20, IL22 and IL24.Component of IL22 receptor formed by IL22RA1 and IL10RB enabling IL22 signaling via JAK/STAT pathways. IL22 also induces activation of MAPK1/MAPK3 and Akt kinases pathways. Component of one of the receptor for IL20 and IL24 formed by IL22RA1 and IL20RB also signaling through STATs activation. Mediates IL24 antiangiogenic activity as well as IL24 inhibitory effect on endothelial cell tube formation and differentiation.
IL-22 R alpha 1 製品リスト
You Have Viewed 0 Of 0 Results
治験薬に関する情報
| 英語名 | 研究コード | 研究開発ステージ | 会社 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|
| Efmarodocokin alfa | RO-7021610; UTTR-1147A; RG-7880 | Phase 2 Clinical | Genentech Inc | Colitis, Ulcerative; Coronavirus Disease 2019 (COVID-19); Crohn Disease; Diabetic Foot; Graft vs Host Disease | 詳細 |
| Temtokibart | ARGX-112; LEO-138559; LP-0145 | Phase 2 Clinical | Argenx Se, Leo Pharma Inc | Dermatitis, Atopic | 詳細 |
| CK-0045 | CK-0045 | Phase 2 Clinical | Cytoki Pharma ApS | Diabetes Mellitus, Type 2; Obesity; Overweight | 詳細 |
| Eflepedocokin alfa | F-652 | Phase 2 Clinical | Evive Biotech Ltd | Acute-On-Chronic Liver Failure; Coronavirus Disease 2019 (COVID-19); Enteritis; Enterocolitis, Necrotizing; Graft vs Host Disease; Hepatitis, Alcoholic; Pancreatitis | 詳細 |
| ABBV-022 | ABBV-022 | Phase 1 Clinical | Abbvie Inc | Colitis, Ulcerative | 詳細 |